sulin-dependent) and Type 2 (non-insulin-dependent) diabetes is complicated since no specific markers are available for either disease. In this study, 244 consecutive patients were diagnosed with diabetes mellitus during two years in Malm6 (230 000 inhabitants), corresponding to an incidence rate of 53.100000 1.year-1. Age, body mass index, HbAlc, C-peptide, and levels of islet cell antibodies were determined at the clinical onset, and related to the classification at diagnosis and at follow-up (n = 233) after a median time of 31 (range 1-49) months. After diagnosis, 42 of 244 (17%) were started on insulin while 202 of 244 (83%) were not. Islet cell antibodies were present in 25 of 42 (60%), and in 18 of 183 (10%), respectively. In the non-insulin treated group, patients with islet cell antibodies had lower body mass index (p < 0.001), higher HbAlc (p < 0.004), and lower C-peptide (p < 0.001) than patients without. At follow-up, 11 of 18 (61%) islet cell positive patients were changed to insulin treatment, as were six other patients. Insulin was discontinued in five initially insulin-treated but islet cell antibody negative patients. The sensitivity, specificity and predictive value for insulin treatment at follow-up were for islet cell antibody positivity; 72%, 96% and 84%, respectively, and for low C-peptide value; 60%, 96%, and 80%, respectively. Islet cell antibodies and low C-peptide at diagnosis of diabetes mellitus are concluded to be useful markers to predict insulin dependence.
The classification of newly diagnosed diabetic patients is, in general, based on clinical observations. The Type 1 (insulin-dependent) diabetic patient is usually young, has rapidly developing symptoms of hyperglycaemia, weight loss and ketoacidosis, while the Type 2 (non-insulin-dependent) patient often is older and overweight with slowly progressive hyperglycaemia, and the majority of the patients are considered as Type 2. There are, however, less clearly classifiable patients, usually middle-or old-aged of normal weight who do not manage to maintain normoglycaemia on diet and oral hypoglycaemic agents (OHA). These patients may progress toward insulin-dependence, but cannot initially be clinically distinguished from other Type 2 diabetic patients. Other patients may present with severe hyperglycaemia requiring immediate treatment with insulin, but can later keep acceptable blood glucose levels on diet alone. A differential diagnosis between Type i and 2 diabetes is important and of interest to the individual patient. In elderly patients severe uncontrolled diabetes has a high rate of mortality [1] , and insulin treatment in patients not needing insulin [2] may result in hyperinsulinaemia, weight gain and, perhaps, accelerated atherosclerosis [3] . Since the aetiologies and pathogeneses of Type 1 and 2 diabetes have yet to be determined, accurate laboratory tests are not available for a differential diagnosis. Low C-peptide [4] , or islet cell antibodies (ICA) [5] [6] [7] [8] [9] , have been suggested as markers for Type 1 diabetes among Type 2 diabetic patients failing on diet and/or OHA. We have tested this hypothesis by a different study design, since in contrast to other studies all consecutive patients with the diagnosis diabetes mellitus have been studied. A total of 244 consecutive patients of all ages with newly diagnosed diabetes mellitus in the city of Malm6, Sweden were followed prospectively with regard to type of treatment. The aims of the study were to determine the predictive values of age, heredity of diabetes, body mass index (BMI), UbAlc, fasting serum Cpeptide, and level of ICA at diagnosis for insulin treatment immediately or at follow-up.
Patients and methods
In 1986, the city of Malm/3 had a population of 230056 inhabitants, of which 14% were under 15 years of age and 39% were 50 years or older. Malm6 General Hospital, affiliated with the University of Lurid, is the only hospital in the city. A Diabetes Care Unit at the hospital takes care of the majority of all newly diagnosed diabetic adults ( _> 15 years of age). In Sweden Type I diabetes is considered a disease to be treated by specialists and these patients are all referred to the Diabetes Care Unit. Some non-insulin requiring patients may attend a limited number of general practitioners and specialists in private practice, who usually refer them to the Diabetes Care Unit for All diabetic patients n=244 Fig.1 . Treatment based on clinical judgement at diagnosis of 244 consecutive patients and at follow-up (median 31 months) in 233 (95%). Eleven patients (5%) were not possible to follow up. The patients were diagnosed consecutively during two years, 1 September, 1985 -31 August, 1987 , in the city of Malta0 diet information, supporting a high ascertainment of Type 2 diabetic patients as well. Children ( < 15 years) with newly diagnosed diabetes are all admitted to the Department of Paediatrics. During the study period information on patients with newly diagnosed diabetes mellitus in Malta0 was collected from the Diabetes Care Unit, and from the departments of Medicine, Endocrinology and Paediatrics at Malm6 General Hospital, and from the private physicians and general practitioners, who were informed about the study.
Patients of all ages with diabetes according to the diagnostic criteria established by The World Health Organisafion (WHO) [10] were included in the study. Patients with the following disorders were excluded: gestational diabetes, diabetes secondary to steroid medication or to alcoholic pancreatitis, and impaired glucose tolerance determined with an oral glucose tolerance test using 75 g glucose. A total of 244 consecutive patients with newly diagnosed diabetes entered the study during the two-year period from September 1985 until August 1987. The family history of diabetes mellitus was obtained from patient records, and was available for 222 of 244 (91%) of the patients. Body mass index (BMI, kg/m z) was calculated in 218 of 244 (89%) of the patients. Blood samples were taken after an overnight fast as soon as possible after diagnosis, but only accepted if taken within three months from diagnosis and within six months after the first hyperglycaemic symptoms. HbAlc was determined in whole blood from 225 of 244 (92%) patients, C-peptide in serum from 212 of 244 (87%) and ICA in serum from 225 of 244 (92%) patients. Several experienced physicians were responsible for the clinical care of the patients, and decisions regarding therapy were in accordance to the criteria recommended by WHO [10] , and based on clinical judgement without knowledge of the results of the biochemical tests except for the HbAI0 values. The therapy one week after diagnosis was defined as the initial therapy. The treatment at follow up, was obtained from the patient records. It was possible to follow 233 of 244 (95%) of the patients for a median time of 31 (range 1-49; quartile range 24-37) months.
The study was approved by the Ethical Committee at the University of Lund, Sweden.
Methods
HbAac. HbA:c was determined by HPLC [11] . The reference values of healthy individuals ranged between 3.9 to 5.3%. The intra-assay coefficient of variation was 1% and the inter-assay 2%.
C-peptide analysis. Serum samples for fasting C-peptide were analysed consecutively to avoid long-term storage and possible degrada-M. Landin-Olsson et al.: Prediction of insulin requirement tion of C-peptide. All samples were analysed as duplicates. The lower detection limit in the radioimmunoassay used [12] was 0.10 nmol/1. Intra-and inter-assay coefficient of variation was 7% and 9%, respectively. Reference values were 0.254).75 nmol/1. The 10th percentile for fasting C-peptide values in the patients initially treated with diet and/or OHA ( < 0.25 nmol/1) was considered as a cut-off limit for a low value, Serum creatinine was within normal range in all patients, except one who had increased values. This patient was excluded, since a decreased glomerular filtration could diminish renal excretion of peptides and give falsely high C-peptide values [13] .
Islet cell antibodies. ICA were titrated in an indirect immunofluorescence assay, incubating sera with unfixed cryocut human pancreas as previously described [14] . Briefly, in a first incubation for 18 h at 4 ~ the serum samples mixed in phosphate buffered saline containing a monoclonal proinsulin antibody to mark pancreatic Beta cells, were applied to the dried pancreatic section. One pancreas was used for all end-point titrations of the samples in this study. After washing, the two fluorescent second antibodies, Texas red-conjugated antimouse IgG (N 2031, Amersham, Buckinghamshire, UK) to visualize the proinsulin antibodies, and FITC-conjugated antihuman IgG (Code F202, Dako, Copenhagen, Denmark) to visualize ICA, were added and incubated with the sections for 30 min at room temperature. After washing, the slides were mounted in TrisHC1 buffered glycerol and evaluated in a fluorescence microscope by at least two independent observers. Quantitation of ICA was done by dilution of sera until ICA were no longer detectable. The interassay variation was 0.65 titration steps. Results were converted to Juvenile Diabetes Foundation (JDF) units [15] , by a standard curve based on the international JDF reference serum sample.
Statistical analysis
All values are given in medians, percentiles or ranges. Comparisons between groups were done with the Mann-Whitney U-test and between frequencies with the chi-square test. Correlations were tested with the Spearman rank correlation test. All tests were two-tailed. A p-value less than 0.05 was considered significant. Sensitivity was defined as the number of patients who were positive for the tested marker at diagnosis expressed as a percent of all diabetic patients who later required insulin treatment. Specificity was defined as the number of patients who were negative for the tested marker as a percent of patients not requiring insulin at follow-up. Predictive value for a positive test was defined as the number of patients who needed insulin at follow-up as a percent of patients who were positive for the tested marker. Predictive value for a negative test was defined as the number of patients who did not need insulin at follow-up as percent of patients who were negative for the tested marker.
Results

All diabetic patients
During the study period of two years, 244 patients with diabetes mellitus were diagnosed, corresponding to an incidence rate of 53-100 000 inhabitants-i. year-~ in the city of Malmd. Insulin treatment was started within one week after diagnosis in 42 of 244 (17%) of the patients. In 202 of 244 (83%) patients, the attending physician considered the disease as non-insulin-requiring and these patients were treated with either diet alone (n = 144), or diet in combination with OHA (n = 58). Of the orginal 244 patients 233 were followed for 1-49 (median 31) months, 5 of 39 (13%) of the initially insulin treated patients were changed to diet and/or OHA, and 17 of 194 (9%) in the initially diet and/or OHA treated group were changed to insulin (Fig 1) . A total of 17 patients in the original cohort died during the observation period, 13non-insulintreated patients, three insulin-treated, and one initially insulin-treated and later on diet. The ages of all patients ranged from 3 to 88 years (median 56 years). The incidence rate for all ages was 53.100 000-1 .year-~ and increased with increasing age, among the 0-14year olds the incidence rate was 17.100 000 children -1 .year-1, and among the 50 year and older 92.100000 -1 .year -~. Age related incidence rates for insulin-and non-insulin-treated diabetes at diagnosis are shown in Figure 2 A. After reclassification according to mode of therapy at follow-up the incidence rates of insulin-and non-insulin-treated diabetes are as in Figure 2 B . The male/female ratio was 1.1 (128/116) for all patients. The annual incidence rates per 100 000 age related inhabitants was 53 for males in all ages, 18 among 0-14 year olds, and 66 among 15-100 year olds. The corresponding incidence rates for females were 48, 16, and 53.100 000-~ .year-i, respectively. There was no significant difference in incidence rates between the sexes in any age group (Fig 2 C) .
Initially insulin treated patients
In the 42 patients treated with insulin within one week from diagnosis, the sex ratio was 0.6 (16 males and 26 females). The age ranged from 3-78 (median 30; quartile range 21-61) years. The age related incidence (Fig. 2 A) for insulin treated patients was bimodal with a first peak in the age group, 10-30 years, and another in the age group 65-80 years. Family history of diabetes was known in 38 of 42 (90%) of the patients, 6 of 38 (16%) had a first degree relative treated with insulin, 6 of 38 (16%) had a diabetic first degree relative not treated with insulin, while 12 of 38 (32%) had a more distant relative and 15 of 38 (39%) did not know of any relative with diabetes mellitus. The frequency distributions for BMI, HbA~o, fasting C-peptide and ICA levels for positive patients are shown in 
Initially non-insulin-treated patients
In the 202patients initially treated with diet and/or OHA, the sex ratio was 1.2 (112 males and 90 females). The age ranged from 6-88 (median 58; quartile range 50-66) years, and the age at diagnosis was significantly higher compared with the initially insulin-treated patients (p < 0.001). The age related incidence was unimodal with peak in the age group 55-69 years ( Fig. 2A) . Heredity of diabetes was known in 184 of 202 (91%) of the patients, insulin treatment in a first degree relative was present in 25 of 184 (14%), 50 of 184 (27%) had a first degree relative with non-insulin-treated diabetes, while 24 of 185 (13%) had a more distant relative and 46% (85 of 184) did not know of any heredity of diabetes. Family history of different types of diabetes did not differ significantly between initially insulin-and non-insulin treated patients. The frequency distributions for BMI, HbAlc, fasting C-peptide and ICA levels are shown in 
Clinical and laboratory parameters at diagnosis in relation to insulin treatment at follow-up
At follow-up 51 of 233 (22%) patients were treated with insulin and 182 of 233 (78%) patients were treated with diet and/or OHA. Compared with the patients remaining on diet and/or OHA (Group D; Table 1), the patients who were changed to insulin treatment (Group C) were already at diagnosis slightly younger, had lower BMI and Cpeptide values, while levels of HbA~o were higher and the frequency of ICA was higher. Compared to the initially insulin-treated patients (Group B), the patients who were changed to insulin therapy (Group C) were older, had slightly higher BMI, while levels of HbAlc, C-peptide and frequency of ICA did not differ (Table 1) .
A total of 18 of 183 (10%) non-insulin-treated patients were ICA positive at the time of clinical diagnosis (patients 1-18; Table 2 ) and 11 of 18 (61%) were changed to insulin treatment during the follow-up period ( Table 2 ). The remaining seven ICA positive patients were after 25-43 months of observation still treated with diet and/or OHA. An additional six initially non-insulin-treated patients (patients 19-24) were changed to insulin therapy at follow-up; five were ICA negative and one not tested ( Table 2) .
The sensitivity, specificity, and predictive value for insulin treatment at follow-up were calculated for age, BMI, HbAlc, C-peptide and ICA. These calculations were done to assess to what extent an analysis of one or several of these parameters at the time of diagnosis would be useful to predict later insulin treatment. The sensitivity of the ICA test was 72% since 36 of 50 of the patients treated with insulin at follow-up were ICA positive at clinical onset. The specificity was 96% since 158 of 165 of the noninsulin-treated patients at follow-up were ICA negative at diagnosis (Table3). The data in Table3 show that presence of ICA at diagnosis predicted later insulin treatment in 84% of the patients. The corresponding values for sensitivity, specificity, and predictive value for tow fasting C-peptide were 60%, 96% and 80%, respectively. The sensitivity was 83% when ICA were positive or C-peptide was low, corresponding to a specificity of 92%. The sensitivity decreased to 49% if the simultaneous presence of ICA and low C-peptide were taken into account. The frequency of falsely insulin requiring patients was, however, as low as 1%, since the specificity increased to 99% (Table 3 ). The probability of being non-insulin requiring at follow-up if the marker was absent is indicated by the predictive value of negative test, which was 92% for ICA alone and 95% when ICA were combined with C-peptide values (Table 3) .
Discussion
The design of our study was to include all patients given the diagnosis diabetes mellitus irrespective of age and classification of type of diabetes based on clinical judgement. Clinical and laboratory parameters were first determined at diagnosis, and by follow-up of the patients it was tested if these parameters predicted insulin treatment. As Table 3 . The sensitivity, specificity and predictive value for insulin treatment at follow-up, of clinical and laboratory parameters obtained at diagnosis of diabetes mellitus in consecutive patients (n = 233). percentile for values recorded at diagnosis in initially diet and/or oral hypoglycaemic expected, patients initially treated with insulin were younger, had lower BMI, more advanced metabolic dysregulation measured as HbAlc, lower fasting C-peptide, and higher frequency of ICA compared with non-insulin treated patients. At follow-up the insulin treated group had increased in number, mainly due to the addition of patients who already at diagnosis had lower BMI and fasting C-peptide, but higher HbA~c and frequency of ICA compared with patients remaining on diet and/or OHA.
Representative study populations are important to enable an accurate estimate of sensitivity, specificity and predictive value. This was possible in the city of Malm6 since it has only one hospital and a limited number of general and private physicians. Furthermore, the incidence rate in younger age groups in this study is in agreement with previous incidence studies of 0-14 year [16] , and 15-34 year [17] olds in Sweden. The sex difference in the 15-34 year olds with a dominance of males [17] , was however, not reproduced in this study, possibly due to the few patients in this age group. Compared to an incidence study in Oslo, Norway [18] , our incidence rates were comparable in ages up to 60 years but lower thereafter. This difference could be explained by different approaches to estimate the incidence rate, or to the possibility that some elderly patients were missed, or to a geographic difference in incidence. The possible missed patients would only influence the results in the unlikely event that ICA were present at a high frequency.
Among the parameters tested, young age was a feature of patients needing insulin at diagnosis, but not for patients changing therapy to insulin-treatment during follow-up. In a Finnish population-based study it was also demonstrated that nearly all patients diagnosed before the age of 19 years were insulin treated, but 37% of all insulin-treated patients were diagnosed after that age [19] . The family history of insulin-or non-insulin treatment in diabetic relatives was found to be common, but not helpful in the classification of the patients. Our data on family history was similar to that reported for Type 1 and 2 diabetic probands [20] . BMI was significantly lower for insulin-treated patients both at diagnosis and at follow-up compared with non-insulin-treated patients. It is clinically well known that insulin-dependent patients tend to be lean. This can partly be explained by age since BMI was positively correlated with age (r~ = 0.71; p < 0.001) in insulin-treated patients at follow-up. BMI is age related in children, but this cannot explain the difference between BMI between group C and D (Table 1) , and may therefore in fact reflect a disturbed Beta-cell function. In accordance to this, the HbAlc values were also higher both in patients needing insulin at diagnosis (Group B) and also in those who were later insulin treated (Group C). Moreover the C-peptide were also lower in these patients.
In previous studies fasting C-peptide [21, 22] , as well as C-peptide stimulation by glucagon have been shown to mark insulin-therapy during follow-up of Type 2 patients [4, 23] . C-peptide is secreted from the pancreatic Betacells equimolar to insulin [24] , and there is a close correlation between fasting C-peptide and C-peptide in response to glucagon [25] . This study lends support to previous investigations, since a low C-peptide would identify 60% of insulin-treated patients. There would be only 4% false positive tests. As shown in Table 3 , insulin treatment could be predicted in 80% of patients with low C-peptide.
Analysis of ICA at diagnosis was the best predictor (84%) and showed the highest sensitivity (72%) for insulin treatment. The high specificity for ICA (96%) was equal to that of fasting C-peptide. The possibility to predict insulin treatment with ICA already at the time of diagnosis was not possible in previous studies of non-insulin-dependent diabetic patients who either failed to control their blood glucose by OHA [5] [6] [7] [8] [9] , or were crosssectional studies [26, 27] . Our finding of a high predictive value of ICA extends studies on consecutively diagnosed non-insulin-treated patients who were either selected [28] or only older than 65 years of age [29] . The high predictive value of ICA among diabetic patients contrasts sharply to the low predictive value in ICA positive first degree relatives [30] [31] [32] as well as in control children [33] . It is, in fact, possible that the predictive value may increase during our prolonged follow-up since it cannot be excluded that the remaining non-insulin-treated ICA positive patients may also develop insulin dependency. The higher ICA levels in the initially non-insulin-treated patients may therefore re-flect an ongoing Beta-cell destruction [34] . It should be noted that all ICA positive patients who were changed to insulin treatment showed low C-peptide values except in two patients (Table 2 ). These two ICA negative patients (patients 23 and 24) had an extremely bad compliance to dietery recommendations and their metabolic regulation was not improved by insulin. It is of interest that ICA negativity was used to predict non-insulin-dependence in diabetic patients [2] . This issue was also elucidated in this study demonstrating a predictive value of 92% for a negative ICA test and 89% for high C-peptide for no need of insulin.
The diagnostic difficulties with classification of diabetes increase with patient age. Type 1 diabetes may occur at any age, and in adults the progression of symptoms may evolve gradually to insulin-dependence [35] . In children almost all receive insulin at diagnosis [19] , but in the middle-aged and elderly patients the development toward insulin-dependency can take years. The frequency of ICA among newly diagnosed children with Type 1 diabetes is about 80% [33, 36] , but appears lower, 60-70% in adults with Type 1 diabetes [34, 37] . Our analysis demonstrates the value of follow up since the frequency of ICA among insulin-treated changed due to altered therapy (Table 1) . It has been speculated that genetic heterogeneity [38] may explain possible clinical differences. We are currently studying whether the addition of genetic markers for HLA-DR and HLA-DQ [39] , determinations of insulin- [40] as well as other autoantibodies [33, 41] may further improve the prediction for insulin treatment in patients with diabetes mellitus.
Determinations of fasting C-peptide and ICA at diagnosis of diabetes seem to be of value in identification of Type 1 diabetic patients. Early insulin treatment may be beneficial to the patient, since insulin therapy may decrease the autoimmune activity directed toward the Betacells. Beta-cells in vitro in a hyperglycaemic environment may be more antigenic, exemplified by glucose-stimulated expression of the Mr 64000 Beta-cell autoantigen [42, 43] . Prophylactic insulin therapy in the spontaneously diabetic BB rat [44] and NOD mouse [45] decreased the frequency of both diabetes and insulitis. Similarly, intensified insulin therapy in patients with new onset Type 1 diabetes seems to preserve residual Beta-cell function in Type 1 diabetic patients [46, 47] . The present study allows us to conclude that ICA and low C-peptide in newly diagnosed patients with diabetes mellitus are useful to predict insulin-dependence. It would therefore be of interest to test whether early and intense insulin therapy in such patients will preserve the residual Beta-cell function. 
Addendum
After the manuscript was submitted five additional initially non-insulin treated ICA positive patients, nos 3, 4, 13, 14 and 17 in Table 2 , have been changed to insulin therapy.
